<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5630">
  <stage>Registered</stage>
  <submitdate>6/07/2012</submitdate>
  <approvaldate>6/07/2012</approvaldate>
  <nctid>NCT01636492</nctid>
  <trial_identification>
    <studytitle>A Study of Bitopertin (RO4917838) in Healthy Male Volunteers</studytitle>
    <scientifictitle>Single Oral Ascending Dose Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4917838 in Healthy Male Volunteers.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BP19292</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteer</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - bitopertin
Treatment: drugs - placebo

Experimental: Bitopertin - 

Placebo Comparator: Placebo - 


Treatment: drugs: bitopertin
Single oral dose

Treatment: drugs: placebo
Single oral dose

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>17 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Area under the concentration-time curve</outcome>
      <timepoint>Pre-dose and 1, 2, 4, 8, 12, 24, 72, 96, 144, 168 (+/-8), 216 (+/-24), 288 (1/-48) hours post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Urine concentrations drug/metabolites</outcome>
      <timepoint>Pre-dose and up to 72 hours post-dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male healthy volunteer, 18 to 60 years of age inclusive

          -  Body mass index (BMI) 19-35 kg/m2 inclusive

          -  Supine blood pressure within the normal range of the center and heart rate &gt;/= 40
             provided QTcB is &lt;450 ms

          -  Subjects must agree to use a barrier method of contraception (e.g. condom) for the
             duration of the study and for 30 days after study completion</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  History or evidence of any clinically significant disease or disorder

          -  Clinically significant ECG abnormalities

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  Previous treatment with iron for iron deficiency anemia

          -  Regular smoker (&gt;10 cigarettes, &gt;3 pipefuls or &gt;3 cigars per day)

          -  History of alcohol and/or drug abuse or addiction within the last 2 years before study
             start

          -  Any confirmed significant allergic reactions against any drug, or multiple allergies
             in the judgment of the investigator

          -  Participation in a clinical study with an investigational drug within the last three
             months prior to screening

          -  Any condition or disease detected during the medical interview/physical examination
             that would render the subject unsuitable for the study, place the subject at undue
             risk or interfere with the ability of the subject to complete the study in the opinion
             of the investigators or their designee</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose />
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>71</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, double-blind, placebo-controlled, dose-escalating study will evaluate the
      safety, tolerability, pharmacokinetics and pharmacodynamics of bitopertin in healthy male
      volunteers. Subjects will be randomized in cohorts to receive single oral doses of either
      bitopertin or placebo.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01636492</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>